Viridian Therapeutics Finalizes $125M Common Stock Offering at $17.00/Share, Part of Larger $350M Capital Raise

summarizeSummary

Viridian Therapeutics finalized a public offering of 7.35 million common shares at $17.00 each, raising $117.0 million net, as part of a larger $350.0 million concurrent capital raise to fund operations and repay debt.

check_boxKey Events

• Finalizes Common Stock Offering

  Viridian Therapeutics is selling 7,352,942 shares of common stock at a public offering price of $17.00 per share, generating estimated net proceeds of approximately $117.0 million. This finalizes the pricing for the common stock portion of the previously announced capital raise.

• Part of Larger Concurrent Capital Raise

  This common stock offering is concurrent with a public offering of $225.0 million in 1.75% Convertible Senior Notes due 2032, bringing the total initial capital raise to $350.0 million. The convertible notes have an initial conversion price of approximately $24.65 per share.

• Significant Dilution to Shareholders

  The offering will result in immediate and substantial dilution for existing shareholders, with the public offering price of $17.00 per share being significantly higher than the pro forma as-adjusted net tangible book value per share. The common stock offering alone represents approximately 7.13% dilution based on current outstanding shares, with potential for further dilution from the convertible notes.

• Use of Proceeds

  Net proceeds from both offerings will be used to repay approximately $50.4 million in outstanding debt under the Hercules Loan and Security Agreement, fund market expansion studies for the TED franchise, advance R&D for earlier pipeline candidates, and for general corporate purposes.

auto_awesomeAnalysis

This filing finalizes the terms and pricing of Viridian Therapeutics' common stock offering, which is a key component of a larger capital raise. The company is selling 7,352,942 shares of common stock at $17.00 per share, generating approximately $117.0 million in net proceeds. This common stock offering is concurrent with a $225.0 million convertible senior notes offering, bringing the total capital raise to $350.0 million (excluding over-allotment options). This substantial capital infusion, representing over 20% of the company's market capitalization, is critical for extending the company's cash runway, especially following the recently reported increased net loss and cash burn in Q1 2026. The proceeds are earmarked for repaying outstanding debt, funding market expansion studies for its TED franchise, and advancing its R&D pipeline. While the offering introduces significant dilution to existing shareholders, it provides essential funding for the company's operations and development, particularly after the positive Phase 3 data for elegrobart announced just days prior, which likely facilitated this successful raise.